<DOC>
	<DOCNO>NCT02897115</DOCNO>
	<brief_summary>A study compare treat-to-target ( T2T ) intense treatment approach participant axial spondyloarthritis ( axSpA ) routine treatment ( Standard Care ( SOC ) ) concern reduction disease activity .</brief_summary>
	<brief_title>A Study Treating Participants With Early Axial Spondyloarthritis ( axSpA ) Taking Intense Treatment Approach Versus Routine Treatment</brief_title>
	<detailed_description />
	<mesh_term>Spondylarthritis</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Signed write informed consent start studyrelated assessment procedure Diagnosis axSpA ( either ankylose spondylitis nonradiographic axSpA ) fulfil ASAS classification criterion axSpA Participants age &gt; = 18 year Disease duration &lt; 5 year Participants must Baseline disease activity define ASDAS &gt; = 2.1 BASDAI &gt; = 4 NSAIDnaive treat maximal recommend NSAID dose last 2 week prior Baseline visit Participants must never fail NSAID take maximal recommend dose 2 week . Contraindications NSAIDs Tumor Necrosis Factor ( TNF ) blocker accord local labeling If enter study concomitant NSAIDs , participant take maximal recommend dose last 2 week prior Baseline Visit fail developed intolerance NSAID take maximal recommend dose 2 week time Prior exposure antiTNF therapy ; biologic therapy potential therapeutic impact SpA , participant treat investigational drug chemical biologic nature within minimum 30 day five halflives ( whichever longer ) drug prior Baseline visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Humira</keyword>
	<keyword>Axial Spondyloarthritis</keyword>
</DOC>